World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
70291
World Ranking
3985
National Ranking
18

Overview

Walter Reinisch is affiliated with the Medical University of Vienna in Austria. Their research focuses primarily on areas within medicine and biochemistry, genetics, and molecular biology. Their work includes substantial contributions to subfields such as genetics, epidemiology, surgery, immunology, and oncology.

The scientist's main areas of study encompass inflammatory bowel disease, microscopic colitis, eosinophilic esophagitis, autoimmune and inflammatory disorders, biosimilars and bioanalytical methods, immunodeficiency and autoimmune disorders, and Helicobacter pylori-related gastroenterology studies.

Walter Reinisch has published extensively in several key journals, with frequent contributions in:

  • Journal of Crohn's and Colitis
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Inflammatory Bowel Diseases
  • Clinical Gastroenterology and Hepatology

Among their recent papers are:

  • STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD, 2021, Gastroenterology
  • Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry, 2020, Gastroenterology
  • Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials, 2022, The Lancet
  • Effect of IBD medications on COVID-19 outcomes: results from an international registry, 2020, Gut
  • Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease, 2021, Gastroenterology

Walter Reinisch frequently collaborates with several coauthors, including:

  • Neeraj Narula
  • Emily C L Wong
  • John K. Marshall
  • Parambir S. Dulai
  • Geert D'Haens

Best Publications

  • Infliximab for induction and maintenance therapy for ulcerative colitis.

    Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch

  • Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

    Jean Frédéric Colombel;William J. Sandborn;Walter Reinisch;Gerassimos J. Mantzaris

  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

    L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

  • STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

    Dan Turner;Amanda Ricciuto;Ayanna Lewis;Ferdinando D’Amico

  • Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

    Paul Moayyedi;Michael G. Surette;Peter T. Kim;Peter T. Kim;Josie Libertucci

  • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

    Wolfgang Hueber;Bruce E Sands;Steve Lewitzky;Marc Vandemeulebroecke

  • Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

    William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens

  • Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

    Axel Dignass;James O. Lindsay;Andreas Sturm;Alastair Windsor

  • Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude

  • European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

    Jean-François Rahier;F Magro;C Abreu;A Armuzzi

  • Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis

    Axel Dignass;Rami Eliakim;Fernando Magro;Christian Maaser

  • Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

    Jean Frédéric Colombel;Paul Rutgeerts;Walter Reinisch;Dirk Esser

  • Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

    Julián Panés;Damián García-Olmo;Gert Van Assche;Jean Frederic Colombel

  • Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

    William J Sandborn;Brian G Feagan;Colleen W Marano;Hongyan Zhang

  • Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Jean Frederic Colombel;Remo Panaccione;Peter Bossuyt;Milan Lukas

  • Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

    Erica J. Brenner;Ryan C. Ungaro;Richard B. Gearry;Gilaad G. Kaplan

  • Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

    William J Sandborn;Brian G Feagan;Colleen W Marano;Hongyan Zhang

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

    J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker

Frequent Co-Authors

William J. Sandborn
William J. Sandborn University of California, San Diego
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
Brian G. Feagan
Brian G. Feagan University of Western Ontario
Remo Panaccione
Remo Panaccione University of Calgary
Silvio Danese
Silvio Danese Vita-Salute San Raffaele University
Stefan Schreiber
Stefan Schreiber Kiel University
Geert R. D'Haens
Geert R. D'Haens University of Amsterdam
Julián Panés
Julián Panés University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA but want alternative options or entry points into healthcare, various online degrees can help you start your journey. Nursing is a popular pathway, and there are easiest rn program to get into options for those seeking less competitive admissions. Some programs also offer a unique advantage by being a nursing school without teas test or HESI requirements, making the process more accessible for aspiring nurses.

Another in-demand field is medical billing and coding. You can find medical billing and coding schools that accept fafsa, which can help lower the cost and provide vital skills for a growing sector. For those with management goals, pursuing the best online healthcare administration degree offers accelerated learning and flexible career opportunities.

Exploring these alternatives not only diversifies your career options but also makes it easier to enter the healthcare field—no matter your background or experience.

Best Scientists Citing Walter Reinisch

Trending Scientists